Our Vision
At OPKO Health, the entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. We are proud of our first in class products, Rayaldee® (calcifediol), and the 4Kscore® test, as well as our diagnostics division, BioReference Laboratories and GeneDx. In addition to our clinical products and diagnostics, we have a robust research and development pipeline and a variety of biomedical and pharmaceutical business solutions.
Our History
Since our founding in 2007, OPKO has grown into a global healthcare company, with over 5,500 employees spanning nine countries, through organic growth and complementary acquisitions.
Timeline
2007
March 2007
The ophthalmic pharmaceutical companies Acuity Pharmaceuticals and the Froptix Corporation merge with eXegenics Inc. to form OPKO Health.
2009
October 2009
OPKO acquires the Chilean pharmaceutical distributor Pharma Genexx S.A., which marks the beginning of OPKO's Latin American presence.
2010
February 2010
OPKO acquires Mexican drug manufacturer and distributor Pharmacos Exakta, S.A. de C.V
December 2010
OPKO and TESARO, Inc. sign an exclusive license agreement for the development and marketing of the oncology support drug, Rolapitant®
2011
September 2011
OPKO agrees to sell its ophthalmic instrumentation business to OPTOS, Inc.
October 2011
OPKO acquires microfluidics based diagnostic test system developer, Claros Diagnostics.
December 2011
OPKO acquires FineTech Pharmaceutical Ltd., an Israeli company which develops and produces high value, high potency active pharmaceutical ingredients (APIs).
2012
January 2012
OPKO acquires the rights to a kallikrein based prostate cancer diagnosis test from Arctic Partners Ab Oy. This test would become a key component of OPKO's 4Kscore® prostate cancer risk assessment laboratory developed test.
August 2012
OPKO acquires Spanish pharmaceutical, nutraceutical and veterinary product company, Farmadiet Group Holding, S.L.
2013
January 2013
OPKO acquires Cytochroma Inc. and their lead nephrology products, Rayaldee® (calcifediol) and Alpharen®.
August 2013
OPKO acquires PROLOR Biotech, with platform technologies to extend the biological half-life of therapeutic proteins and peptides. This technology is used in OPKO's late clinical stage product Somatrogon©, for the treatment of growth hormone deficiency (GHD), and in a Factor VIIa product for the treatment of hemophilia A & B.
2014
March 2014
OPKO launches the 4Kscore® test in the United States (U.S). The 4Kscore® test is a laboratory developed test and is suggested to be used after an elevated prostate specific antigen (PSA) test result to risk stratify the detection of aggressive prostate cancer.
May 2014
OPKO presents data demonstrating that the 4Kscore® is an accurate, sensitive, and personalized predictor of high-grade prostate cancer at the American Urological Association Plenary Session.
September 2014
OPKO launches the 4Kscore® test in Europe.
